1 study found for:    weill | Open Studies | "Cholangitis, Sclerosing"
Show Display Options
Rank Status Study
1 Recruiting Simtuzumab (GS-6624) in the Prevention of Progression of Liver Fibrosis in Subjects With Primary Sclerosing Cholangitis (PSC)
Condition: Primary Sclerosing Cholangitis (PSC)
Interventions: Biological: Simtuzumab;   Biological: Placebo

Indicates status has not been verified in more than two years